Search

The report is presented at a time of growing European debate over the implementation of the Directive, following the European Parliament’s call for a new assessment and the recent conclusions of the

In Spain, nearly one million people were living with dementia in 2025, according to estimates from Alzheimer Europe, with Alzheimer’s disease accounting for between 60% and 70% of cases.

Meet our new AseBio member, Oncomatryx. We spoke with Pedro Esnaola, Chief Public Affairs Officer.

The COVID-19 pandemic transformed mRNA technology into a large-scale clinical platform and demonstrated its ability to rapidly design and update vaccines in response to new antigens.

Biobide has grown its ecotoxicology service line into a more comprehensive GLP-certified testing platforms — now spanning terrestrial, sediment, avian, pollinator, endocrine and environmental fate

Through two sessions organised by AseBio focusing on the Biotech Act I and II, we will analyse the measures needed to strengthen innovation, investment, biomanufacturing and biotechnology value chains

Oryzon Genomics will participate in several international investment and capital markets events in the United States and Europe throughout September and October. The biopharmaceutical company will

Together with clinical experts, researchers and our partner Viva In Vitro Diagnostics, we analyse the main challenges in addressing sepsis and how new biomarkers and biotechnological tools can

€3.1 million financing led by new investor Clave Capital, with participation from existing investors.

Cesif promotes the training of professionals capable of transforming research and scientific knowledge into business projects, innovative solutions and new opportunities for the biotechnology sector.

On the occasion of World Agriculture Day, at AseBio we explore, together with our member Phoenix Biosolutions, how biotechnology solutions based on microalgae and biostimulants can contribute to more

Cell and gene therapies are transforming biomedical innovation, but their development presents significant challenges in terms of characterization, safety, efficacy, and scalability. Agilent addresses

The arrival of Quantexa marks the launch of Node I's innovation community, bringing together pioneering organisations working in advanced technology.

BCN HEALTH has published the study “Chronic Kidney Disease (CKD): Systematic Review of the Cost Effectiveness of SGLT2 Inhibitors and Other Novel Nephroprotective Drugs” in PharmacoEconomics, an

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of an inadequate response to S1P receptor-modulating therapies.

As a sponsor of the Health track at BIOSPAIN 2026, Lonza will contribute its expertise to some of the key discussions shaping the future of healthcare and biotechnology. We spoke with Alice Harrison